A T-cell redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T-cells, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, pasritamig binds to both CD3 on T-cells and KLK2 on KLK2-expressing tumor cells. The resulting cross-linkage activates and redirects T-cells to KLK2-expressing tumor cells. This results in T-cell-mediated lysis of KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.